Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors
Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors
复制标题
DOI：
10.1258/0956462054308404
复制
发表时间：
2005-07-01
影响因子：
1.4
通讯作者：
Jevtovic, D
中科院分区：
文献类型：
--
作者：
Dunic, I;Djurkovic-Djakovic, O;Jevtovic, D
在2000年1月1日至2001年7月31日期间，对115例经诊断为艾滋病并开始接受高效抗逆转录病毒治疗（HAART）的患者进行了一项前瞻性研究，以评估带状疱疹（HZ）作为艾滋病患者在HAART期间免疫恢复疾病的发病率。其中，14例（12%）患者在HAART治疗后1个月和15个月（中位数8个月）内发生了单次皮节HZ发作。HZ患者与非HZ患者在年龄、性别和HIV传播危险因素方面相似，但具有更晚期的疾病。与基线值相比，病毒载量显著降低（P < 0.01），而平均CD 4 + T细胞计数在HZ发作时（或非HZ患者的等效值）增加近4倍（P < 0.01），但HZ患者仍低于400/mL。HAART期间HZ是宿主免疫应答改善的免疫病理学结果，与免疫恢复的开始相关。
A prospective study to evaluate the incidence of herpes zoster (HZ) as an immune restoration disease in patients with AIDS during highly active antiretroviral therapy (HAART) was conducted in a series of 115 patients diagnosed with AIDS initiated on HAART between 1 January 2000 and 31 July 2001. Of these, a single dermatomal HZ episode occurred in 14 (12%) patients within one and 15 months of HAART (median eight months). The HZ patients were similar to the non-HZ patients in age, sex, and HIV transmission risk factor, but had a more advanced disease. Compared with the baseline values, the viral loads significantly (P < 0.01) decreased, while the mean CD4 + T-cell counts increased by almost four-fold (P < 0.01) in both groups at the time of the HZ episode (or equivalent in non-HZ), but remained below 400/mL in the HZ patients. HZ during HAART is an immunopathological consequence of the improvement of the host immune response, correlating with the beginning of immune restoration.